RAC 0.59% $1.71 race oncology ltd

Industry news, page-1834

  1. 19,186 Posts.
    lightbulb Created with Sketch. 6182
    The two together are critical to commercial success. Just getting rid of cardiotoxicity doesn’t get you a commercial drug as the developers of dexrazoxane discovered and as Neefjes has discovered trying to advance aclarubicin. Success will require showing in the clinic that bisantrene both improves doxorubicin anticancer activity AND makes it safer. This won’t be easy (nothing in clinical research ever is), but the potential makes it worth the effort.
    Last edited by Davisite: 28/07/24
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.71
Change
0.010(0.59%)
Mkt cap ! $291.3M
Open High Low Value Volume
$1.76 $1.79 $1.66 $307.6K 176.7K

Buyers (Bids)

No. Vol. Price($)
1 615 $1.62
 

Sellers (Offers)

Price($) Vol. No.
$1.74 609 1
View Market Depth
Last trade - 16.10pm 02/09/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.